Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Imaging
Published in: Cancer Imaging 1/2014

Open Access 01-12-2014 | Review

The role of magnetic resonance imaging in the management of brain metastases: diagnosis to prognosis

Authors: Rasheed Zakaria, Kumar Das, Maneesh Bhojak, Mark Radon, Carol Walker, Michael D Jenkinson

Published in: Cancer Imaging | Issue 1/2014

Login to get access

Abstract

This article reviews the different MRI techniques available for the diagnosis, treatment and monitoring of brain metastases with a focus on applying advanced MR techniques to practical clinical problems. Topics include conventional MRI sequences and contrast agents, functional MR imaging, diffusion weighted MR, MR spectroscopy and perfusion MR. The role of radiographic biomarkers is discussed as well as future directions such as molecular imaging and MR guided high frequency ultrasound.
Appendix
Available only for authorised users
Literature
1.
Soffietti R, Rudā R, Mutani R: Management of brain metastases. J Neurol 2002, 249: 1357–1369. 10.1007/s00415-002-0870-6CrossRefPubMed
2.
Gavrilovic IT, Posner JB: Brain metastases: epidemiology and pathophysiology. J Neuro-Oncol 2005, 75: 5–14. 10.1007/s11060-004-8093-6CrossRef
3.
Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G: Epidemiology of metastatic brain tumors. Neurosurg Clin N Am 2011, 22(1):1–6. v 10.1016/j.nec.2010.08.007CrossRefPubMed
4.
5.
Mills SJ, Thompson G, Jackson A: Advanced magnetic resonance imaging biomarkers of cerebral metastases. Cancer Imaging 2012, 12: 245–252. 10.1102/1470-7330.2012.0012CrossRefPubMedPubMedCentral
6.
Young RJ, Sills AK, Brem S, Knopp EA: Neuroimaging of metastatic brain disease. Neurosurgery 2005, 57(5 SUPPL):S4–10-S4–23.
7.
8.
Kaal EC, Taphoorn MJ, Vecht CJ: Symptomatic management and imaging of brain metastases. J Neurooncol 2005, 75(1):15–20. 10.1007/s11060-004-8094-5CrossRefPubMed
9.
Brandão LA, Shiroishi MS, Law M: Brain tumors. A multimodality approach with diffusion-weighted imaging, diffusion tensor imaging, magnetic resonance spectroscopy, dynamic susceptibility contrast and dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging Clin N Am 2013, 21(2):199–239. 10.1016/j.mric.2013.02.003CrossRefPubMed
10.
Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37: 745–751. 10.1016/S0360-3016(96)00619-0CrossRefPubMed
11.
Jenkinson MD, Haylock B, Shenoy A, Husband D, Javadpour M: Management of cerebral metastasis: evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy. Eur J Cancer 2011, 47(5):649–655. 10.1016/j.ejca.2010.11.033CrossRefPubMed
12.
Nieder C, Marienhagen K, Astner ST, Molls M: Prognostic scores in brain metastases from breast cancer. BMC Cancer 2009, 9: 105. 10.1186/1471-2407-9-105CrossRefPubMedPubMedCentral
13.
Siu TL, Jeffree RL, Fuller JW: Current strategies in the surgical management of cerebral metastases: an evidence-based review. J Clin Neurosci 2011, 18(11):1429–1434. 10.1016/j.jocn.2011.04.002CrossRefPubMed
14.
Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M: Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012, 30(4):419–425. 10.1200/JCO.2011.38.0527CrossRefPubMed
15.
Davis PC, Hudgins PA, Peterman SB, Hoffman JC Jr: Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging. Am J Neuroradiol 1991, 12(2):293–300.PubMedPubMedCentral
16.
Yokoi K, Kamiya N, Matsuguma H, Machida S, Hirose T, Mori K, Tominaga K: Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI. Chest 1999, 115(3):714–719. 10.1378/chest.115.3.714CrossRefPubMed
17.
Schellinger PD, Meinck HM, Thron A: Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999, 44(3):275–281. 10.1023/A:1006308808769CrossRefPubMed
18.
Kruger S, Mottaghy FM, Buck AK, Maschke S, Kley H, Frechen D, Wibmer T, Reske SN, Pauls S: Brain metastasis in lung cancer. Comparison of cerebral MRI and 18F-FDG-PET/CT for diagnosis in the initial staging. Nuklearmedizin 2011, 50(3):101–106.CrossRefPubMed
19.
Schneider G, Kirchin MA, Pirovano G, Colosimo C, Ruscalleda J, Korves M, Salerio I, La Noce A, Spinazzi A: Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: Effect of dose on lesion detection and delineation. J Magn Reson Imaging 2001, 14: 525–539. 10.1002/jmri.1216CrossRefPubMed
20.
Sze G, Johnson C, Kawamura Y, Goldberg SN, Lange R, Friedland RJ, Wolf RJ: Comparison of single- and triple-dose contrast material in the MR screening of brain metastases. AJNR Am J Neuroradiol 1998, 19(5):821–828.PubMedPubMedCentral
21.
Yuh WTC, Tali ET, Nguyen HD, Simonson TM, Mayr NA, Fisher DJ: The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. Am J Neuroradiol 1995, 16(2):373–380.PubMedPubMedCentral
22.
Anzalone N, Essig M, Lee SK, Dörfler A, Ganslandt O, Combs SE, Picozzi P: Optimizing contrast-enhanced magnetic resonance imaging characterization of brain metastases: relevance to stereotactic radiosurgery. Neurosurgery 2013, 72(5):691–701. 10.1227/NEU.0b013e3182889ddfCrossRefPubMed
23.
Ginsberg LE, Lang FF: Neuroradiologic screening for brain metastases–can quadruple dose gadolinium be far behind? AJNR Am J Neuroradiol 1998, 19(5):829–830.PubMedPubMedCentral
24.
Haba D, Pasco Papon A, Tanguy JY, Burtin P, Aube C, Caron-Poitreau C: Use of half-dose gadolinium-enhanced MRI and magnetization transfer saturation in brain tumors. Eur Radiol 2001, 11(1):117–122. 10.1007/s003300000493CrossRefPubMed
25.
Chen W, Wang L, Zhu W, Xia L, Qi J, Feng D, Luo X: Multicontrast single-slab 3D MRI to detect cerebral metastasis. AJR Am J Roentgenol 2012, 198(1):27–32. 10.2214/AJR.11.7030CrossRefPubMed
26.
Kakeda S, Korogi Y, Hiai Y, Ohnari N, Moriya J, Kamada K, Hanamiya M, Sato T, Kitajima M: Detection of brain metastasis at 3T: comparison among SE, IR-FSE and 3D-GRE sequences. Eur Radiol 2007, 17(9):2345–2351. 10.1007/s00330-007-0599-9CrossRefPubMed
27.
Nagai A, Nagai A, Shibamoto Y, Mori Y, Hashizume C, Hagiwara M, Kobayashi T: Increases in the number of brain metastases detected at frame-fixed, thin-slice MRI for gamma knife surgery planning. Neuro Oncol 2010, 12(11):1187–1192. 10.1093/neuonc/noq084CrossRefPubMedPubMedCentral
28.
Brodbelt A: Delaying emergency treatment for patients with cerebral abscesses and brain tumours: a consequence of the neuroscience MDT? Br J Neurosurg 2012, 26(3):325. 10.3109/02688697.2012.680628CrossRefPubMed
29.
Desprechins B, Stadnik T, Koerts G, Shabana W, Breucq C, Osteaux M: Use of diffusion-weighted MR imaging in differential diagnosis between intracerebral necrotic tumors and cerebral abscesses. AJNR Am J Neuroradiol 1999, 20(7):1252–1257.PubMedPubMedCentral
30.
Ebisu T, Tanaka C, Umeda M, Kitamura M, Naruse S, Higuchi T, Ueda S, Sato H: Discrimination of brain abscess from necrotic or cystic tumors by diffusion-weighted echo planar imaging. Magn Reson Imaging 1996, 14(9):1113–1116. 10.1016/S0730-725X(96)00237-8CrossRefPubMed
31.
Kim YJ, Chang KH, Song IC, Kim HD, Seong SO, Kim YH, Han MH: Brain abscess and necrotic or cystic brain tumor: discrimination with signal intensity on diffusion-weighted MR imaging. AJR Am J Roentgenol 1998, 171(6):1487–1490. 10.2214/ajr.171.6.9843275CrossRefPubMed
32.
Krabbe K, Gideon P, Wagn P, Hansen U, Thomsen C, Madsen F: MR diffusion imaging of human intracranial tumours. Neuroradiology 1997, 39: 483–489. 10.1007/s002340050450CrossRefPubMed
33.
Fertikh D, Krejza J, Cunqueiro A, Danish S, Alokaili R, Melhem ER: Discrimination of capsular stage brain abscesses from necrotic or cystic neoplasms using diffusion-weighted magnetic resonance imaging. J Neurosurg 2007, 106(1):76–81. 10.3171/jns.2007.106.1.76CrossRefPubMed
34.
Tomar V, Yadav A, Rathore RK, Verma S, Awasthi R, Bharadwaj V, Ojha BK, Prasad KN, Gupta RK: Apparent diffusion coefficient with higher b-value correlates better with viable cell count quantified from the cavity of brain abscess. AJNR Am J Neuroradiol 2011, 32(11):2120–2125. 10.3174/ajnr.A2674CrossRefPubMedPubMedCentral
35.
Duygulu G, Ovali GY, Calli C, Kitis O, Yünten N, Akalin T, Islekel S: Intracerebral metastasis showing restricted diffusion: correlation with histopathologic findings. Eur J Radiol 2010, 74(1):117–120. 10.1016/j.ejrad.2009.03.004CrossRefPubMed
36.
Hayashida Y, Hirai T, Morishita S, Kitajima M, Murakami R, Korogi Y, Makino K, Nakamura H, Ikushima I, Yamura M, Kochi M, Kuratsu JI, Yamashita Y: Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol 2006, 27(7):1419–1425.PubMedPubMedCentral
37.
Holtas S, Geijer B, Strömblad LG, Maly-Sundgren P, Burtscher IM: A ring-enhancing metastasis with central high signal on diffusion-weighted imaging and low apparent diffusion coefficients. Neuroradiology 2000, 42(11):824–827. 10.1007/s002340000431CrossRefPubMed
38.
Stadnik TW, Chaskis C, Michotte A, Shabana WM, van Rompaey K, Luypaert R, Budinsky L, Jellus V, Osteaux M: Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings. AJNR Am J Neuroradiol 2001, 22(5):969–976.PubMedPubMedCentral
39.
Bulakbasi N, Kocaoglu M, Farzaliyev A, Tayfun C, Ucoz T, Somuncu I: Assessment of diagnostic accuracy of perfusion MR imaging in primary and metastatic solitary malignant brain tumors. AJNR Am J Neuroradiol 2005, 26: 2187–2199.PubMedPubMedCentral
40.
Calli C, Kitis O, Yunten N, Yurtseven T, Islekel S, Akalin T: Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 2006, 58(3):394–403. 10.1016/j.ejrad.2005.12.032CrossRefPubMed
41.
Chiang IC, Kuo YT, Lu CY, Yeung KW, Lin WC, Sheu FO, Liu GC: Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology 2004, 46(8):619–627.CrossRefPubMed
42.
Lee EJ, terBrugge K, Mikulis D, Choi DS, Bae JM, Lee SK, Moon SY: Diagnostic value of peritumoral minimum apparent diffusion coefficient for differentiation of glioblastoma multiforme from solitary metastatic lesions. AJR Am J Roentgenol 2011, 196(1):71–76. 10.2214/AJR.10.4752CrossRefPubMed
43.
Wang S, Kim S, Chawla S, Wolf RL, Knipp DE, Vossough A, O'Rourke DM, Judy KD, Poptani H, Melhem ER: Differentiation between glioblastomas and solitary brain metastases using diffusion tensor imaging. Neuroimage 2009, 44(3):653–660. 10.1016/j.neuroimage.2008.09.027CrossRefPubMed
44.
Byrnes TJ, Barrick TR, Bell BA, Clark CA: Diffusion tensor imaging discriminates between glioblastoma and cerebral metastases in vivo. NMR Biomed 2011, 24(1):54–60. 10.1002/nbm.1555CrossRefPubMed
45.
Price SJ, Gillard JH: Imaging biomarkers of brain tumour margin and tumour invasion. Br J Radiol 2011, 84 Spec No 2: S159–67.PubMed
46.
Tsuchiya K, Fujikawa A, Nakajima M, Honya K: Differentiation between solitary brain metastasis and high-grade glioma by diffusion tensor imaging. Br J Radiol 2005, 78(930):533–537. 10.1259/bjr/68749637CrossRefPubMed
47.
Toh CH, Wei KC, Ng SH, Wan YL, Lin CP, Castillo M: Differentiation of brain abscesses from necrotic glioblastomas and cystic metastatic brain tumors with diffusion tensor imaging. AJNR Am J Neuroradiol 2011, 32(9):1646–1651. 10.3174/ajnr.A2581CrossRefPubMedPubMedCentral
48.
Bulakbasi N, Kocaoglu M, Ors F, Tayfun C, Uçöz T: Combination of single-voxel proton MR spectroscopy and apparent diffusion coefficient calculation in the evaluation of common brain tumors. AJNR Am J Neuroradiol 2003, 24(2):225–233.PubMedPubMedCentral
49.
Pinker K, Stadlbauer A, Bogner W, Gruber S, Helbich TH: Molecular imaging of cancer: MR spectroscopy and beyond. Eur J Radiol 2012, 81(3):566–577. 10.1016/j.ejrad.2010.04.028CrossRefPubMed
50.
van der Graaf M: In vivo magnetic resonance spectroscopy: basic methodology and clinical applications. Eur Biophys J 2010, 39(4):527–540. 10.1007/s00249-009-0517-yCrossRefPubMed
51.
Server A, Josefsen R, Kulle B, Maehlen J, Schellhorn T, Gadmar Ø, Kumar T, Haakonsen M, Langberg CW, Nakstad PH: Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors. Acta Radiol 2010, 51(3):316–325. 10.3109/02841850903482901CrossRefPubMed
52.
Wong CS, Chu TYC, Ma JKF: Peri-tumoural magnetic resonance spectroscopy to differentiate solitary primary intra-axial high-grade glioma and brain metastasis: a pilot study. J Hong Kong College Radiologists 2010, 13(4):195–198.
53.
Crisi G, Orsingher L, Filice S: Lipid and macromolecules quantitation in differentiating glioblastoma from solitary metastasis: A short-echo time single-voxel magnetic resonance spectroscopy study at 3 T. J Comput Assist Tomogr 2013, 37(2):265–271. 10.1097/RCT.0b013e318282d2baCrossRefPubMed
54.
Ha DH, Choi S, Oh JY, Yoon SK, Kang MJ, Kim KU: Application of 31P MR spectroscopy to the brain tumors. Korean J Radiol 2013, 14(3):477–486. 10.3348/kjr.2013.14.3.477CrossRefPubMedPubMedCentral
55.
Blasel S, Jurcoane A, Franz K, Morawe G, Pellikan S, Hattingen E: Elevated peritumoural rCBV values as a mean to differentiate metastases from high-grade gliomas. Acta Neurochir 2010, 152(11):1893–1899. 10.1007/s00701-010-0774-7CrossRefPubMed
56.
Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW: High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002, 222: 715–721. 10.1148/radiol.2223010558CrossRefPubMed
57.
Lacerda S, Law M: Magnetic resonance perfusion and permeability imaging in brain tumors. Neuroimaging Clin N Am 2009, 19(4):527–557. 10.1016/j.nic.2009.08.007CrossRefPubMed
58.
Thompson G, Mills SJ, Stivaros SM, Jackson A: Imaging of brain tumors: perfusion/permeability. Neuroimaging Clin N Am 2010, 20(3):337–353. 10.1016/j.nic.2010.04.008CrossRefPubMed
59.
Server A, Graff BA, Døli Orheim TE, Schellhorn T, Josefsen R, Gadmar OB, Nakstad PH: Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis. Neuroradiology 2011, 53(5):319–330. 10.1007/s00234-010-0740-3CrossRefPubMed
60.
Farquharson S, Tournier JD, Calamante F, Fabinyi G, Schneider-Kolsky M, Jackson GD, Connelly A: White matter fiber tractography: why we need to move beyond DTI. J Neurosurg 2013, 118(6):1367–1377. 10.3171/2013.2.JNS121294CrossRefPubMed
61.
Walter J, Kuhn SA, Waschke A, Kalff R, Ewald C: Operative treatment of subcortical metastatic tumours in the central region. J Neurooncol 2011, 103(3):567–573. 10.1007/s11060-010-0420-5CrossRefPubMed
62.
Paek SH, Audu PB, Sperling MR, Cho J, Andrews DW: Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery 2005, 56(5):1021–1033.PubMed
63.
Tan TC, Black PM: Image-guided craniotomy for cerebral metastases: techniques and outcomes. Neurosurgery 2007, 61(1 Suppl):349–356. discussion 356–7CrossRefPubMed
64.
Chernov MF, Ono Y, Kubo O, Hori T: Comparison of 1H-MRS-detected metabolic characteristics in single metastatic brain tumors of different origin. Brain Tumor Pathol 2006, 23(1):35–40. 10.1007/s10014-006-0198-5CrossRefPubMed
65.
Huang BY, Kwock L, Castillo M, Smith JK: Association of choline levels and tumor perfusion in brain metastases assessed with proton MR spectroscopy and dynamic susceptibility contrast-enhanced perfusion weighted MRI. Technol Cancer Res T 2010, 9: 327–337.CrossRef
66.
Kang TW, Kim ST, Byun HS, Jeon P, Kim K, Kim H, Lee JI: Morphological and functional MRI, MRS, perfusion and diffusion changes after radiosurgery of brain metastasis. Eur J Radiol 2009, 72(3):370–380. 10.1016/j.ejrad.2008.08.009CrossRefPubMed
67.
Friedman DP, Morales RE, Goldman HW: MR imaging findings after stereotactic radiosurgery using the gamma knife. AJR Am J Roentgenol 2001, 176(6):1589–1595. 10.2214/ajr.176.6.1761589CrossRefPubMed
68.
Lunsford LD, Kondziolka D, Maitz A, Flickinger JC: Black holes, white dwarfs and supernovas: imaging after radiosurgery. Stereotact Funct Neurosurg 1998, 70(Suppl 1):2–10.CrossRefPubMed
69.
Peterson AM, Meltzer CC, Evanson EJ, Flickinger JC, Kondziolka D: MR imaging response of brain metastases after gamma knife stereotactic radiosurgery. Radiology 1999, 211(3):807–814. 10.1148/radiology.211.3.r99jn48807CrossRefPubMed
70.
Dequesada IM, Dequesada IM, Quisling RG, Yachnis A, Friedman WA: Can standard magnetic resonance imaging reliably distinguish recurrent tumor from radiation necrosis after radiosurgery for brain metastases? A radiographic-pathological study. Neurosurgery 2008, 63(5):898–903. discussion 904 10.1227/01.NEU.0000333263.31870.31CrossRefPubMed
71.
Stockham AL, Tievsky AL, Koyfman SA, Reddy CA, Suh JH, Vogelbaum MA, Barnett GH, Chao ST: Conventional MRI does not reliably distinguish radiation necrosis from tumor recurrence after stereotactic radiosurgery. J Neurooncol 2012, 109(1):149–158. 10.1007/s11060-012-0881-9CrossRefPubMed
72.
Barajas RF, Chang JS, Sneed PK, Segal MR, McDermott MW, Cha S: Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2009, 30(2):367–372.CrossRefPubMedPubMedCentral
73.
Hoefnagels FW, Lagerwaard FJ, Sanchez E, Haasbeek CJ, Knol DL, Slotman BJ, Vandertop WP: Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence. J Neurol 2009, 256(6):878–887. 10.1007/s00415-009-5034-5CrossRefPubMedPubMedCentral
74.
Goldman M, Boxerman JL, Rogg JM, Norén G: Utility of apparent diffusion coefficient in predicting the outcome of Gamma Knife-treated brain metastases prior to changes in tumor volume: a preliminary study. J Neurosurg 2006, 105(Suppl):175–182.CrossRefPubMed
75.
Spanberger T, Berghoff AS, Dinhof C, Ilhan-Mutlu A, Magerle M, Hutterer M, Pichler J, Wöhrer A, Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Marosi C, Birner P, Prayer D, Preusser M: Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. Clin Exp Metastasis 2013, 30(4):357–368. 10.1007/s10585-012-9542-9CrossRefPubMed
76.
Berghoff AS, Spanberger T, Ilhan-Mutlu A, Magerle M, Hutterer M, Woehrer A, Hackl M, Widhalm G, Dieckmann K, Marosi C, Birner P, Prayer D, Preusser M: Preoperative diffusion-weighted imaging of single brain metastases correlates with patient survival times. PLoS One 2013, 8(2):e55464. 10.1371/journal.pone.0055464CrossRefPubMedPubMedCentral
77.
Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W: A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008, 70(2):510–514. 10.1016/j.ijrobp.2007.06.074CrossRefPubMed
78.
Torigian DA, Zaidi H, Kwee TC, Saboury B, Udupa JK, Cho ZH, Alavi A: PET/MR imaging: technical aspects and potential clinical applications. Radiology 2013, 267(1):26–44. 10.1148/radiol.13121038CrossRefPubMed
79.
Serres S, Soto MS, Hamilton A, McAteer MA, Carbonell WS, Robson MD, Ansorge O, Khrapitchev A, Bristow C, Balathasan L, Weissensteiner T, Anthony DC, Choudhury RP, Muschel RJ, Sibson NR: Molecular MRI enables early and sensitive detection of brain metastases. Proc Natl Acad Sci U S A 2012, 109(17):6674–6679. 10.1073/pnas.1117412109CrossRefPubMedPubMedCentral
80.
Jethwa PR, Barrese JC, Gowda A, Shetty A, Danish SF: Magnetic resonance thermometry-guided laser-induced thermal therapy for intracranial neoplasms: initial experience. Neurosurgery 2012, 71(1 Suppl Operative):133–144. 144–5CrossRefPubMed
81.
Ram Z, Cohen ZR, Harnof S, Tal S, Faibel M, Nass D, Maier SE, Hadani M, Mardor Y: Magnetic resonance imaging-guided, high-intensity focused ultrasound for brain tumor therapy. Neurosurgery 2006, 59(5):949–955. discussion 955–6CrossRefPubMed
82.
Monteith S, Sheehan J, Medel R, Wintermark M, Eames M, Snell J, Kassell NF, Elias WJ: Potential intracranial applications of magnetic resonance-guided focused ultrasound surgery. J Neurosurg 2013, 118(2):215–221. 10.3171/2012.10.JNS12449CrossRefPubMed
Metadata
Title
The role of magnetic resonance imaging in the management of brain metastases: diagnosis to prognosis
Authors
Rasheed Zakaria
Kumar Das
Maneesh Bhojak
Mark Radon
Carol Walker
Michael D Jenkinson
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cancer Imaging / Issue 1/2014
Electronic ISSN: 1470-7330
DOI
https://doi.org/10.1186/1470-7330-14-8

Other articles of this Issue 1/2014

Cancer Imaging 1/2014 Go to the issue

Research article

Clinical evaluation of semi-automatic landmark-based lesion tracking software for CT-scans

Research article

Prediction of poorly differentiated hepatocellular carcinoma using contrast computed tomography

Research article

Muscle metastases: comparison of features in different primary tumours

Review

Prognostic factors in advanced pharyngeal and oral cavity cancer; significance of multimodality imaging in terms of 7th edition of TNM

Editorial

Cancer imaging: Quo vadis?

Case series

Asymptomatic myocardial metastasis from cancers of upper aero-digestive tract detected on FDG PET/CT: a series of 4 cases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits